法国药物不良反应致住院发生率及可预防性:IATROSTAT前瞻性观察研究
该研究在法国随机选取公立医院内科病房,于2018年4–7月纳入一周内入院患者,由区域药物警戒中心网络收集药物不良反应相关住院(ADR-HA)病例并由独立委员会验证。结果显示ADR-HA发生率为8.5%(95%CI 7.6–9.4%),随年龄增长而升高,16.1%的病例因用药不符合说明书或指南而被判定为可预防。
要点
- 法国ADR-HA发生率为8.5%,显著高于2007年报告的3.6%。
- 发生率随年龄升高:≥65岁为10.6%,≤16岁为3.3%。
- 16.1%的ADR-HA因用药不符合说明书或指南而可预防。
核心结论
- 法国ADR-HA发生率在近十年间大幅上升,相当比例涉及新型药理类别且被判定为可预防。
研究设计与样本
- 前瞻性多中心观察研究,在随机选取的法国公立医院内科病房于2018年4–7月开展,纳入一周内入院患者,由法国区域药物警戒中心网络收集病例,独立委员会验证病例及可预防性。
主要发现
- ADR-HA总体发生率为8.5%(95%CI 7.6–9.4%)。
- 发生率随年龄升高:≤16岁为3.3%(95%CI 1.8–5.5%),≥65岁为10.6%(95%CI 9.3–12.0%)。
- 最常见ADR为出血事件(8.8%)、血液学异常(6.5%)、急性肾衰竭(6.3%)、水电解质紊乱(6.0%)和跌倒(5.2%)。
- 涉及新药:靶向治疗占抗肿瘤药的22.8%,直接口服抗凝药占抗血栓药的29.6%,肠促胰素类药物占降糖药的20.0%。
- 16.1%的ADR可预防,原因为用药不符合说明书、包装 leaflets 或其他治疗指南。
关键数值与推荐
- 可预防病例中不符合情形主要为剂量或疗程(27.9%)、警告(23.2%)、使用注意事项(18.6%)及患者不当自我药疗或误用(11.6%)。
临床怎么用
- 临床药师应关注高龄患者及新型药物(靶向治疗、直接口服抗凝药、肠促胰素类药物)的用药监护,并依据说明书和指南审核剂量、疗程及警告事项以减少可预防的ADR-HA。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: In the last French study in 2007, the incidence of hospital admissions (HAs) related to adverse drug reactions (ADRs) was 3.6%. The objective was to assess the current ADR-HA incidence in France and to describe both its characteristics and preventability. METHODS: A prospective multicentre study was conducted among randomly selected French public hospital medical wards (April-July 2018). Patients admitted during a week period were included. ADR-HA cases were collected by the French Regional Pharmacovigilance Centres network. An independent committee validated potential cases and ADR preventability. RESULTS: ADR-HA incidence was 8.5% (95% confidence interval [CI]: 7.6-9.4%), increasing with age (3.3% [95%CI: 1.8-5.5%] ≤16 y vs. 10.6% [95%CI: 9.3-12.0%] ≥65 y). The most common ADRs were haemorrhagic events (8.8%), haematological disorders (6.5%), acute renal failure (6.3%), fluid and electrolyte disorders (6.0%), and falls (5.2%). New drugs were involved: targeted therapies (22.8% of antineoplastics), direct oral anticoagulants (29.6% of antithrombotics) and incretin-based drugs (20.0% of antidiabetics). ADRs were preventable in 16.1% of cases because the drugs involved had not been used in accordance with monographies, package leaflets or other therapeutic guidelines. The main situations of noncompliance addressed either dose or duration of use (27.9%), warning (23.2%), use precaution (18.6%) and inappropriate self-medication or misuse by patients (11.6%). CONCLUSION: In France, ADR-HA incidence dramatically increased over the last decade. A significant proportion was related to new pharmacological classes and considered as preventable. These findings should lead to in-depth thought on preventive actions on at-risk drug classes.
引用
- Laroche ML, Gautier S, Polard E, et al. Incidence and preventability of hospital admissions for adverse drug reactions in France: A prospective observational study (IATROSTAT). Br J Clin Pharmacol. 2022. PMID: 36002314. doi:10.1111/bcp.15510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。